(Press-News.org) Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The authors note that these findings do not provide a definitive conclusion regarding the safety of PrEP therapy prior to pregnancy. The issue is being released early to coincide with the International AIDS Conference.
Antiretroviral pre-exposure prophylaxis as daily oral tenofovir disoproxil fumarate (TDF) and co-formulated emtricitabine/tenofovir disoproxil fumarate (FTC+TDF) has been demonstrated to be efficacious for the prevention of human immunodeficiency virus (HIV) acquisition in diverse populations. PrEP could be an important component of safer conception strategies for women at risk for HIV infection, including those in HIV-serodiscordant couples (i.e., in which only one member is HIV infected), but the effect on pregnancy outcomes is not well defined, according to background information in the article.
Nelly R. Mugo, M.B.Ch.B., M.P.H., of the Kenya Medical Research Institute, Nairobi, Kenya, and University of Washington, Seattle, and colleagues conducted further follow-up of the Partners PrEP Study, a randomized, placebo-controlled trial of PrEP for HIV prevention among HIV-serodiscordant couples conducted between July 2008 and June 2013. For this analysis, which included 1,785 couples in Kenya and Uganda, the researchers assessed pregnancy incidence and outcomes among women using PrEP during the periconception period. Females had been randomized to daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 2011, when PrEP demonstrated efficacy for HIV prevention. Thereafter, participants continued receiving active PrEP without placebo.
A total of 431 pregnancies occurred. The researchers found that pregnancy incidence did not differ significantly by study group, and that there was no statistically significant association between women receiving PrEP and those receiving placebo and the occurrence of pregnancy losses, which was 42.5 percent for women receiving FTC+TDF, 32.3 percent for those receiving placebo, and 27.7 percent for those receiving TDF alone. After July 2011 (when the placebo group was discontinued), the frequency of pregnancy loss was 37.5 percent for FTC+TDF and 36.7 percent for TDF alone.
Occurrence of preterm birth, congenital anomalies, kidney function and growth throughout the first year of life did not differ significantly for infants born to women who received PrEP vs placebo.
The authors write that for some outcomes, including pregnancy loss, preterm birth, congenital anomalies, and infant mortality, confidence intervals were wide (suggesting uncertainty in the result and the need for more data), including both a null effect and potential harm, and thus definitive statements about safety of PrEP in the periconception period cannot be made.
"These results should be discussed with HIV-uninfected women receiving PrEP who are considering becoming pregnant."
(doi:10.1001/jama.2014.8735; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Integrating HIV Prevention Into Practice
Bradley M. Mathers, M.B.Ch.B., M.D., and David A. Cooper, M.D., D.Sc., of the University of New South Wales, Sydney, Australia, comment on the findings of this study in an accompanying editorial.
"… it appears (from the magnitude and asymmetry of the confidence intervals) that there may be a signal suggesting potential harm as pregnancy loss based on the emtricitabine/tenofovir vs placebo comparison (absolute difference ending in pregnancy loss of 10.2 percent) and on the post hoc emtricitabine/tenofovir vs tenofovir alone comparison (absolute difference ending in pregnancy loss of 9.2 percent)."
"These intriguing findings reported by Mugo et al provide important information from one of the largest studies of exposure to these nucleoside analogues in HIV-negative persons and therefore must be considered carefully. Tenofovir and emtricitabine are both category B drugs, but this signal suggesting a possible association with pregnancy loss has not to date appeared in studies of HIV-infected persons, suggesting that this observation deserves evaluation in future studies. Moreover, the nucleosides were stopped according to the trial protocol no later than 6 weeks into the pregnancy, albeit this period is highly sensitive to subsequent adverse pregnancy outcomes, but exposure to these drugs may be longer in the real-world setting."
INFORMATION:
(doi:10.1001/jama.2014.8606; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
Study examines effect on pregnancy of receiving antiretroviral therapy for preventing HIV
2014-07-19
ELSE PRESS RELEASES FROM THIS DATE:
Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
2014-07-19
In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent. The issue is being released early to coincide with the International AIDS Conference.
In human immunodeficiency virus (HIV) infection, abdominal fat accumulation ...
Offering option of initial HIV care at home increases use of ART
2014-07-19
LSTM Researchers found that offering adults in Malawi optional home initiation of care following HIV self-testing resulted in a significant increase in the proportion of adults initiating antiretroviral therapy (ART) compared with standard HIV care.
The results are part of a study that was funded by the Wellcome Trust and published in the July 23/30 issue of JAMA, which is HIV/AIDS themed and released early to coincide with the International AIDS Conference taking place in Melbourne, Australia next week.
In 2012 it was estimated that 35 million people worldwide were living ...
Hepatitis C cured in co-infected HIV patients
2014-07-19
A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.
"In many settings, hepatitis C is now a leading cause of death among HIV co-infected patients," says Mark Sulkowski, M.D., medical director of the Johns Hopkins Infectious Disease Center for Viral Hepatitis and professor of medicine at the Johns Hopkins University School of Medicine. Approximately one-third of HIV patients in the United States have hepatitis C, with an estimated ...
Feinstein Institute researchers identify brain network
2014-07-19
Manhassett, NY – Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.
Parkinson's disease is the second most common neurodegenerative disease in the US. Those who suffer from Parkinson's disease most often experience tremors, slowness of movement (bradykinesia), rigidity, and impaired balance and coordination. Patients may have difficulty walking, ...
Performance improvement program helps doctors better manage depression, reports journal of psychiatric practice
2014-07-18
A performance improvement initiative for physicians can significantly increase their use of evidence-based practices in screening for and treating depression, in the July Journal of Psychiatric Practice. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Led by Dr Michael E. Thase of the University of Pennsylvania Medical School, the researchers evaluated a performance improvement continuing medical education (PI CME) program to increase physicians' use of practices that have been shown to improve diagnosis and care for depression. ...
NASA sees powerful thunderstorms in Tropical Storm Matmo
2014-07-18
Strong thunderstorms reaching toward the top of the troposphere circled Tropical Storm Matmo's center and appeared in a band of thunderstorms on the storm's southwestern quadrant. Infrared imagery from NASA's Aqua satellite showed very cold temperatures that indicated the high cloud tops in the powerful storms.
Tropical cyclones consist of hundreds of thunderstorms. When NASA's Aqua satellite flew over Tropical Storm Matmo on July 17 at 16:59 UTC (12:59 p.m. EDT) on July 17, the Atmospheric Infrared Sounder (AIRS) instrument obtained infrared data on the tropical cyclone. ...
High-dose fluticasone effective against eosinophilic esophagitis
2014-07-18
Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with EoE are steroid-resistant. By analyzing gene expression—the degree to which certain genes are turned on or off—in esophageal ...
Experts urge new discipline combining benefits of neuroscience and psychology treatments
2014-07-18
When a patient talks with a psychological therapist, what changes occur in the patient's brain that relieve mental disorders? UCLA psychology professor Michelle Craske says the honest answer is that we don't know. But, according to Craske and two colleagues, we need to find out.
Mental health disorders — such as depression, schizophrenia, post-traumatic stress disorder, obsessive–compulsive disorder and eating disorders — affect 1 in 4 people worldwide. Psychological treatments "hold the strongest evidence base for addressing many such conditions," but they need improvement, ...
Tea Party support linked to educational segregation, new study shows
2014-07-18
In January of 2009, Barack Obama assumed the U.S. presidency in the midst of the most severe recession since the great depression of the 1930s. While many Americans hoped the new administration would take an active role in providing relief for those harmed by the economic collapse, a "Tea Party" movement emerged to oppose Obama's agenda.
University of Notre Dame political sociologist Rory McVeigh, whose study, "Educational Segregation, Tea Party Organizations, and Battles over Distributive Justice," was recently published in the American Sociological Review, says "The ...
Yale researchers identify targets for immunotherapy in early-stage breast cancer
2014-07-18
July 17, 2014, New Haven, CT – Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials. The findings ...